Drug intelligence / Profile preview

influenza a (h1n1) vaccine (surface antigen, inactivated)

Development stage
Unknown
Lead developer
Novartis
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

The a/h1n1 subunit influenza vaccine is a monovalent, inactivated vaccine designed to provide active immunization against the Influenza A virus subtype H1N1, specifically the strain responsible for the 2009 pandemic (A/California/07/2009-like). As a subunit (or surface antigen) vaccine, it contains purified viral proteins—primarily hemagglutinin (HA) and neuraminidase (NA)—rather than the whole or split virus. These antigens are typically extracted from virus particles grown in embryonated chicken eggs or cell cultures through a process of chemical disruption and purification. Upon administration, the vaccine stimulates the immune system to produce neutralizing antibodies against the HA protein, which prevents the virus from attaching to and entering host respiratory cells. Subunit vaccines are generally associated with a lower reactogenicity profile compared to whole-virus or split-virion vaccines. A prominent example of this type is Novartis's Focetria, which was often formulated with the MF59 adjuvant to enhance the immune response in the context of pandemic preparedness.

Brand names
Focetria
Other names
a/h1n1 subunit influenza vaccinemonovalent h1n1 subunit vaccineh1n1 surface antigen vaccineh-1n1 surface antigen vaccineh 1n1 surface antigen vaccineinactivated h1n1 subunit influenza vaccine
02

Targets

NeuraminidaseHA (Hemagglutinin (Influenza A virus subtype H1N1))

Beyond the preview

Go deeper on influenza a (h1n1) vaccine (surface antigen, inactivated).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on influenza a (h1n1) vaccine (surface antigen, inactivated).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call